epitalon comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-02. Numbers and descriptions here follow the published literature rather than marketing material.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four residues, linear chain |
| Residue sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Calculated mass | 390.3 daltons | Value for the free, uncharged form |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility | Freely soluble in water | Often handled as a salt form |
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
== External links == The Accreditation Council for Graduate Medical Education in the United States The American Osteopathic Association Accreditation for osteopathic residency Educational Commission for Foreign Medical Graduates Robert N. Wilkey, Federal Whistleblower Protection: A Means to Enforcing Maximum Hour Legislation for Medical Residents, William Mitchell Law Review, Vol. 30, Issue 1 (2003)
== Side effects == Side effects of tiagabine are dose-related. The most common side effect of tiagabine is dizziness. Other side effects that have been observed with a rate of statistical significance relative to placebo include asthenia, somnolence, nervousness, memory impairment, tremor, headache, diarrhea, and depression. Adverse effects such as confusion, aphasia, stuttering, and paresthesia (a tingling sensation in the body's extremities, particularly the hands and fingers) may occur at higher dosages of the drug (e.g., over 8 mg/day). Tiagabine has been associated with new-onset seizures and status epilepticus in people without epilepsy in post-marketing surveillance. This may be dose-related, although it has been reported at doses of as low as 4 mg/day, and may also be related to concomitant use of other medications that lower the seizure threshold. Some of these seizures occurred around the time of dose increases. There may be an increased risk of psychosis with tiagabine treatment, although data is mixed and inconclusive. Tiagabine can also reportedly interfere with visual color perception. It has not been found to cause psychomotor, cognitive, or memory impairment. Unlike certain other GABAergic drugs like muscimol, gaboxadol, and CI-966, tiagabine has not been associated with hallucinogenic effects.
== Pharmacokinetics == The substance is absorbed quickly from the gut and reaches its maximum plasma concentration (Cmax) after about two hours. If applied rectally, Cmax is reached after four hours. The bioavailability of the suppositories, measured as area under the curve (AUC), is about twofold that of oral formulations, due to a first pass effect of over 50%. By far the most important metabolisation reaction is ester hydrolysis, which accounts for 26.3% of the total clearance through the kidneys. Only 0.37% are cleared in form of the original substance. The plasma half life is 2.3 hours for oral formulations and three to 3.5 hours for suppositories. Pentoxyverine is also excreted into the breast milk.
In August 2011, there was a 12-week double-blind, placebo controlled phase 2 trial that focused on elderly men and postmenopausal women which concluded that enobosarm showed statistically significant improvements in total lean body mass and physical function without apparent adverse effects on hair growth or sebum production. In August 2013, GTx announced that enobosarm had failed in two phase 3 clinical trials to treat wasting in people with lung cancer. The company had invested around $35 million in the development of the drug. The company said at that time that it planned to pursue approval of enobosarm in Europe; the company was also still developing GTx-758, a nonsteroidal estrogen, for castration-resistant prostate cancer. As of 2018, enobosarm was the only SARM to have reached or completed phase 3 clinical trials. In 2016, GTx began phase 2 trials, to see if enobosarm might be effective to treat stress urinary incontinence in women. In 2018, GTx announced the phase 2 trials on the effectiveness of enobosarm for stress urinary incontinence in women failed to achieve its primary endpoint in the ASTRID Trial. By September 2023, development of enobosarm for stress urinary incontinence had been discontinued. In 2022, the FDA granted fast tract designation to enobosarm in AR+, ER+, HER2- metastatic breast cancer. In January 2024, Veru Inc. submitted an Investigational New Drug application to the FDA of enobosarm for prevention of muscle loss and augmentation of fat loss in combination with glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide for weight loss.
These methods include personal sampling, where samplers are located in the personal breathing zone of the worker, often attached to a shirt collar to be as close to the nose and mouth as possible; and area/background sampling, where they are placed at static locations. The assessment should use both particle counters, which monitor the real-time quantity of nanomaterials and other background particles; and filter-based samples, which can be used to identify the nanomaterial, usually using electron microscopy and elemental analysis. As of 2016, quantitative occupational exposure limits have not been determined for most nanomaterials. The U.S. National Institute for Occupational Safety and Health has determined non-regulatory recommended exposure limits for carbon nanotubes, carbon nanofibers, and ultrafine titanium dioxide. Agencies and organizations from other countries, including the British Standards Institute and the Institute for Occupational Safety and Health in Germany, have established OELs for some nanomaterials, and some companies have supplied OELs for their products. Nanoscale diagnostics Nanotechnology has been making headlines in the medical field, being responsible for biomedical imaging. The unique optical, magnetic and chemical properties of materials on the Nano scale has allowed the development of imaging probes with multi-functionality such as better contrast enhancement, better spatial information, controlled bio distribution, and multi-modal imaging across various scanning devices.
Sources: en.wikipedia.org
=== Analogues === Nalorphine has a number of analogues including niconalorphine (the nicomorphine analogue), diacetylnalorphine (heroin analogue), dihydronalorphine (dihydromorphine), and a number of others as well as a number of codeine-based analogues.
Arsenic trioxide, even at low concentrations, causes the degradation of PML/RARα, thereby partially restoring the differentiation of cancerous promyelocytes. Arsenic trioxide activates JNK (c-Jun N-terminal kinase), also known as stress-activated protein kinase, which belongs to the MAPK (mitogen-activated protein kinase) family. These enzymes play a crucial role in signal transduction within the cell. Under normal conditions, JNK is activated by the phosphorylation of threonine and tyrosine residues. However, studies on specific cell lines derived from patients with acute promyelocytic leukemia have demonstrated that this activation also occurs in response to arsenic trioxide. It seems that the activation of JNK leads to the phosphorylation of both anti-apoptotic proteins (Bcl-2, Bcl-Xl) and pro-apoptotic proteins – Bax (Bcl-2-associated X protein), Bak (Bcl-2 homologous killer), and Bid (BH3 interacting domain death agonist) – effectively activating them. Pro-apoptotic proteins contain the BH3 domain, which is responsible for their "death-inducing" activity. They cause the formation of ion channels in the mitochondrial membrane, resulting in the release of the aforementioned apoptotic factors into the cytoplasm. Anti-apoptotic proteins owe their function to a hydrophobic cleft in their spatial structure that binds to the BH3 domain, thereby neutralizing the effects of the "death" proteins. Under normal conditions, the decision for a cell to undergo apoptosis depends on the ratio of pro-apoptotic to anti-apoptotic proteins.
Amino acids: glutamate, aspartate, D-serine, gamma-aminobutyric acid (GABA), glycine Gasotransmitters: nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S) Monoamines: Catecholamines: dopamine (DA), norepinephrine (noradrenaline, NE), epinephrine (adrenaline) Indolamines: serotonin (5-HT, SER), melatonin histamine Trace amines: phenethylamine, N-methylphenethylamine, tyramine, 3-iodothyronamine, octopamine, tryptamine, etc. Peptides: oxytocin, somatostatin, substance P, cocaine and amphetamine regulated transcript, opioid peptides Purines: adenosine triphosphate (ATP), adenosine Others: acetylcholine (ACh), anandamide, etc. In addition, over 100 neuroactive peptides have been found, and new ones are discovered regularly. Many of these are co-released along with a small-molecule transmitter. Nevertheless, in some cases, a peptide is the primary transmitter at a synapse. Beta-endorphin is a relatively well-known example of a peptide neurotransmitter because it engages in highly specific interactions with opioid receptors in the central nervous system. Single ions (such as synaptically released zinc) are also considered neurotransmitters by some, as well as some gaseous molecules such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S). The gases are produced in the neural cytoplasm and are immediately diffused through the cell membrane into the extracellular fluid and into nearby cells to stimulate production of second messengers.
In plants, algae, cyanobacteria, and phototrophic and chemoautotrophic Pseudomonadota (formerly referred to as proteobacteria), the enzyme usually consists of two types of protein subunit, called the large chain (L, about 55,000 Da) and the small chain (S, about 13,000 Da). The large-chain gene (rbcL) is encoded by the chloroplast DNA in plants. There are typically several related small-chain genes in the nucleus of plant cells, and the small chains are imported to the stromal compartment of chloroplasts from the cytosol by crossing the outer chloroplast membrane. The enzymatically active substrate (ribulose 1,5-bisphosphate) binding sites are located in the large chains that form dimers in which amino acids from each large chain contribute to the binding sites. A total of eight large chains (= four dimers) and eight small chains assemble into a larger complex of about 540,000 Da. In some Pseudomonadota and dinoflagellates, enzymes consisting of only large subunits have been found. Magnesium ions (Mg2+) are needed for enzymatic activity. Correct positioning of Mg2+ in the active site of the enzyme involves addition of an "activating" carbon dioxide molecule (CO2) to a lysine in the active site (forming a carbamate). Mg2+ operates by driving deprotonation of the Lys210 residue, causing the Lys residue to rotate by 120 degrees to the trans conformer, decreasing the distance between the nitrogen of Lys and the carbon of CO2. The close proximity allows for the formation of a covalent bond, resulting in the carbamate.
Sources: en.wikipedia.org
== Social and cultural implications == Nipple pain during breastfeeding may affect the family life of mothers. On average, mothers and infants need to make 36 visits to healthcare providers for nipple pain in their first year, leading to a huge household expense. Meanwhile, mothers may shorten breastfeeding duration and switch to artificial infant milk in order to prevent suffering from the pain. Besides, the painful experience may affect the relationship between parents and children as mothers may develop depression, tension and mood disturbances during breastfeeding.
Everything the intelligentsia had ever hoped for in terms of freedom of expression and publication was suddenly available. Thanks to glasnost, the Soviet press was full of informed, detailed criticisms of historical ‘mistakes’ such as collectivization, the Great Purges, bad decisions in World War II, wartime ethnic deportations and postwar anti-Semitism. Newspapers and thick journals competed with each other for exposés, publishing all the manuscripts in drawers that had hitherto been forbidden and pushing for rehabilitation of fallen revolutionary heroes. It was a wonderful time to be a Soviet writer of a certain age and type—a Khrushchevian truth-teller whose realist novels and plays unmasked social ills, historical cover-ups and political scandals. It was an equally exciting time to be a Soviet reader, except that there was too much to read, and what one read was likely to shake one's faith in the Soviet system. Gorbachev's assumption, like that of the old reform-minded thick journals, was that 'telling the truth' could not but be good, ultimately strengthening the Soviet system by purifying it. Unfortunately, the opposite proved to be the case. The effect of the crash course on the flaws of Soviet socialism was to undermine the public’s confidence rather than rally it for reform. Additionally, the internal political reforms associated with perestroika altered both the political consciousness of Soviet society and the strategic outlook of Soviet foreign policy.
==== Prescription drug prices ==== In December 2025, President Trump announced a deal in which nine major pharmaceutical companies will in 2026 begin offering "Most Favored Nation" pricing to state Medicaid programs. In return, the companies will receive a reduction in tariffs for three years. This announcement brings the total to 14 out of the 17 largest pharmaceutical manufacturers agreeing to this deal, leaving AbbVie, Johnson & Johnson, and Regeneron as the major holdouts. In 2026, the Trump administration plans to start a website named TrumpRx which will not sell drugs directly, but will give patients information and links on pricing. Trump officials said the deal also included more than $150 billion for new investment within the U.S. In addition, several of the companies will be donating pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve. Senior citizens on Medicare will see lower prices in 2026 from the first negotiated prices going into effect from the Inflation Reduction Act (IRA) signed in 2022 by President Biden. This includes blood thinners such as Eliquis and Xarelto and diabetes drugs such as Jardiance and Januvia. However, a negative feature of the Inflation Adjustment Act is, that since it penalizes year-to-year increases in drug prices, drug companies have responded by setting higher starting prices.
This partnership has resulted in a long list of medical milestones, including the development of chemotherapy; the first use of an immunotoxin to treat a malignancy; identification of the genes that cause kidney cancer, leading to the development of six new, targeted treatments for advanced kidney cancer; the discovery that lithium helps depression; the first gene therapy; the first AIDS treatment; and the development of tests to detect AIDS/HIV and hepatitis viruses in blood, which led to a safer blood supply. The NIH Clinical Center sees 10,000 new research participants a year from around the world.
== Usage == The dalton is commonly used in physics and chemistry to express the mass of atomic-scale objects, such as atoms, molecules, and elementary particles, both for discrete instances and multiple types of ensemble averages. For example, an atom of helium-4 has a mass of 4.0026 Da. This is an intrinsic property of the isotope and all helium-4 atoms have the same mass. Acetylsalicylic acid (aspirin), C9H8O4, has an average mass of about 180.157 Da. However, there are no acetylsalicylic acid molecules with this mass. The two most common masses of individual acetylsalicylic acid molecules are 180.0423 Da, having the most common isotopes, and 181.0456 Da, in which one carbon is carbon-13. The molecular masses of proteins, nucleic acids, and other large polymers are often expressed with the unit kilodalton (kDa) and megadalton (MDa). Titin, one of the largest known proteins, has a molecular mass of between 3 and 3.7 megadaltons. The DNA of chromosome 1 in the human genome has about 249 million base pairs, each with an average mass of about 650 Da, or 156 gigadalton (GDa) total. In general, the mass in daltons of an atom is numerically close but not exactly equal to the number of nucleons (protons and neutrons) in its nucleus. It follows that the molar mass of a compound (grams per mole) is numerically close to the average number of nucleons contained in each molecule. By definition, the mass of an atom of carbon-12 is 12 daltons, which corresponds with the number of nucleons that it has (6 protons and 6 neutrons).
Sources: en.wikipedia.org
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.
Epithalamin refers to a crude preparation derived from bovine pineal tissue, which contains many components. Epitalon is a single synthetic tetrapeptide identified from that material and produced by chemical synthesis. The two names are sometimes confused because early reports treated the synthetic peptide as an active fragment of the extract.
It has been registered for clinical use in Russia, where it is associated with a small family of short peptides. In most other jurisdictions it is not an approved medicine and is traded as a research chemical. Regulatory status varies by country and changes over time.
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.